SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential, djmurdock
Search This Board: 
Last Post: 9/18/2017 10:40:31 AM - Followers: 61 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects 08:45 AM
ZYNE News: Biosynthesis Technology Could Transform Cannabinoid Production 09/13/2017 08:45:00 AM
ZYNE News: Current Report Filing (8-k) 09/11/2017 05:02:12 PM
ZYNE News: Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences 09/06/2017 07:30:00 AM
ZYNE News: MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing 08/30/2017 10:29:33 PM
News News Alert: Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects 09/19/2017 08:45:00 AM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#811   Bought the dip @ 5.54. Cheers. DunnQ 09/18/17 10:40:31 AM
#810   September surfgreen 09/07/17 02:18:51 PM
#809   When do you think results are due? mwhite57 09/07/17 11:27:41 AM
#808   Hoping the CEO will outline a plan to surfgreen 09/06/17 07:34:15 PM
#807   Seems a little high. I think 15 if mwhite57 08/30/17 09:46:07 AM
#806   Ha! Dreaming of that outcome surfgreen 08/27/17 08:16:39 PM
#805   WoW everyone Left? come on FragileX open label Bescaredxx 08/27/17 06:40:40 PM
#803   https://seekingalpha.com/article/4099061-zynerba-2-strikes Inoviorulez 08/15/17 07:06:03 PM
#802   Yes could be, if you are very, very careful... CoachMarc 08/15/17 09:57:44 AM
#801   Good bottom flip tho. Mr_Popeye 08/15/17 09:51:29 AM
#800   They failed their last 2 trials, so they CoachMarc 08/15/17 09:50:20 AM
#799   Obviously it's in a very indecisive spot... Mr_Popeye 08/15/17 09:44:27 AM
#798   Downgraded by Oppenheimer AND by Jefferies... CoachMarc 08/15/17 09:42:52 AM
#797   Upgraded to buy at Roth Capital. PT $15 Mr_Popeye 08/15/17 09:41:02 AM
#796   I don't think so, ZYNE was downgraded this morning... CoachMarc 08/15/17 09:35:05 AM
#795   I really anticipate that we will be up stocky101 08/15/17 08:06:46 AM
#794   They are moving into P3 with the drug, MoToM 08/14/17 02:39:30 PM
#793   Does this stock have any chance of recovering surfgreen 08/14/17 10:10:19 AM
#792   I TOOK ADVATAGE FROM THE COLAPSATION.LOL.AND MADE OVER ORCA 08/14/17 09:37:30 AM
#791   Getting smashed this am, gonna have to trade @WolfofWeedST 08/14/17 08:46:12 AM
#790   Uh oh ! $zyne Cbdpotential 08/14/17 08:44:01 AM
#789   DUE TO SMALL FLOAT,THIS THING GETS KILLED.I AM ORCA 08/14/17 08:28:23 AM
#788   WOW.ANOTHER ROUND OF UGLY RESULTS.THIS COULD GET TO ORCA 08/14/17 08:13:25 AM
#787   Wow what a POS Bescaredxx 08/14/17 07:55:59 AM
#786   Are results expected tomorrow or next week? mwhite57 08/13/17 03:44:51 PM
#785   Gotta watch the options... https://finance.yahoo.com/news/options-traders-betti @WolfofWeedST 08/11/17 11:34:45 PM
#784   We get a good result this is back @WolfofWeedST 08/11/17 03:07:46 PM
#783   Tons of accumulation on this day of shorts. MoToM 08/11/17 01:12:43 PM
#782   Quote: "DON'T QUESTION THE PROS." CoachMarc 08/11/17 10:22:48 AM
#781   LOL BOYS.THE PPS SPEAKS VOLUMES.DON'T QUESTION THE PROS. ORCA 08/11/17 10:17:00 AM
#780   Could you explain to all of us how CoachMarc 08/11/17 10:09:54 AM
#779   He is posting old news because he has CoachMarc 08/11/17 10:02:55 AM
#778   Why are you posting old news? we all Bescaredxx 08/11/17 09:16:21 AM
#777   BAD NEWS.ZYN002 missing all endpoints in the study ORCA 08/11/17 08:24:53 AM
#776   THIS BAD NEWS SHOULD TAKE IT TO AROUND ORCA 08/11/17 08:18:20 AM
#775   Hahahah just yesterday they were reporting it as MoToM 08/11/17 02:17:08 AM
#774   https://seekingalpha.com/article/4097618-zynerbas-phase-2-results-indicate-major Inoviorulez 08/10/17 05:03:55 PM
#773   ..OWC* is open for business and I almost ddbl_our_buck 08/09/17 05:34:23 PM
#772   * * $ZYNE Video Chart 08-09-17 * * ClayTrader 08/09/17 05:10:29 PM
#771   Do you guys believe me now? florida investor 08/09/17 04:25:25 PM
#770   Seems like the fix is in. Bad news MoToM 08/09/17 02:17:44 PM
#769   Looks like it's going to blow its load a surfer 08/09/17 02:16:16 PM
#768   SUPPORT WAS AT 6.00!!! this was screaming buy!!!! austinogg 08/09/17 02:15:35 PM
#767   This runs until OA data. MoToM 08/09/17 02:14:21 PM
#766   What the hell happened here? Loosingstocks 08/09/17 09:14:30 AM
#765   ???? 3 Biotech Bellwethers That Have Taken A SBPartners 08/09/17 07:51:47 AM
#764   20 yr investor what are the most important austinogg 08/08/17 01:07:20 PM
#763   global what is the support of this stock austinogg 08/08/17 01:01:05 PM
#762   $30 to $7 price target. Going to $5 Global Supermodel 08/08/17 09:57:23 AM
#761   42 years of age, 20 years of education, florida investor 08/08/17 07:21:26 AM
PostSubject